Inovio Pharmaceuticals discussed progress on DNA medicine platform development in Q3 2024, focusing on INO-3107 for RRP treatment. Positive immunology data, regulatory discussions, and financial discipline were highlighted. Plans for BLA submission, commercialization, and pipeline advancement were emphasized.